EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Androgen deprivation therapy — known as ADT — is a hormone treatment that's commonly prescribed for men with advanced prostate cancer because it blocks the testosterone on which the cancer feeds.

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.